---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-049874"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:32:01.431442+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma

## Summary
- Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.
- Tender offer accepted 38.8M shares (~77.2% of outstanding); merger completed April 28, 2026.
- Expected EPS dilution of ~$5.57-$5.67 in 2026; ex-R&D, modestly dilutive 2026-27, accretive from 2028.
- Full control of anito-cel eliminates profit-sharing/royalty obligations; accelerates development and commercial launch.
- Arcellx becomes wholly owned subsidiary of Gilead; ACLX common stock to be delisted from Nasdaq.

## SEC filing metadata
- accession: 0001104659-26-049874
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/0001104659-26-049874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/tm2612748d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-049874
- JSON: https://secwatch.observer/filing/0001104659-26-049874.json
- Plain text: https://secwatch.observer/filing/0001104659-26-049874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.